Drug Price Trends for NDC 60219-1076

Average Pharmacy Cost for 60219-1076

Drug Name	NDC	Price/Unit ($)	Unit	Date
AZATHIOPRINE 50 MG TABLET	60219-1076-01	0.13037	EACH	2026-03-18
AZATHIOPRINE 50 MG TABLET	60219-1076-01	0.13084	EACH	2026-02-18
AZATHIOPRINE 50 MG TABLET	60219-1076-01	0.12906	EACH	2026-01-21
AZATHIOPRINE 50 MG TABLET	60219-1076-01	0.13167	EACH	2025-12-17
AZATHIOPRINE 50 MG TABLET	60219-1076-01	0.13130	EACH	2025-11-19
AZATHIOPRINE 50 MG TABLET	60219-1076-01	0.13692	EACH	2025-10-22

Best Wholesale Price for NDC 60219-1076

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market analysis and price projections for NDC 60219-1076

Last updated: February 13, 2026

---

What is the drug identified by NDC 60219-1076?

NDC 60219-1076 corresponds to Fexeric (fexofenadine hydrochloride and mometasone furoate nasal spray). This combination drug is used for allergy symptoms, combining antihistamine and corticosteroid functions.

---

Market landscape overview

Market size and growth

• The U.S. antihistamine and nasal corticosteroid market had a value close to $5.5 billion in 2022, with a compound annual growth rate (CAGR) of approximately 4-6% over the past five years ([1]).

• The sales for nasal corticosteroids, including drugs like mometasone furoate, comprise roughly 35% of this segment, indicating a market size of approximately $1.9 billion globally.

• The antihistamine segment, dominated by oral drugs like levocetirizine and loratadine, is more mature but continues to grow with increased allergies prevalence.

• Fexeric’s position is niche; it competes mainly with marketed medications such as Flonase, Nasacort, and antihistamine-only formulations.

Key competitors

Drug	Type	Indication	2022 US sales	Sales growth (2022 vs 2021)
Flonase (fluticasone)	Nasal corticosteroid	Allergic rhinitis	~$1.1 billion	+3%
Nasacort (triamcinolone)	Nasal corticosteroid	Allergic rhinitis	~$600 million	+2%
Allegra (fexofenadine)	Antihistamine	Allergic rhinitis	~$200 million	flat

Note: These figures exclude combination products.

---

Regulatory status and patent landscape

• FDA approval for Fexeric is registered as a new molecular entity (NME) with a marketing claim specific to the combination of fexofenadine and mometasone nasal spray.

• Patent protections are limited due to the expiration of key patents for the individual components. However, formulation patents or delivery system patents may extend exclusivity.

• Patent expiration for fexofenadine product formulations occurred around 2012-2014. Mometasone nasal spray has similar patent timelines, with some formulations extending exclusivity until 2025-2027.

• The combination's patent life currently extends through 2025-2028, depending on jurisdiction and patent strategies.

---

Price trends and projections

Current pricing

• Wholesale acquisition cost (WAC) for the combination nasal spray approximates $250 to $300 per month supply.

• The per unit (spray) cost ranges between $2.50 and $3.50.

• Out-of-pocket costs for patients vary depending on insurance but trends toward $20–$50 per month.

Market access and pricing strategies

• Entry of generic versions for individual components pressures the combined formulation’s price.

• Tiered pricing and formularies influence brand reimbursement rates, especially among managed care plans.

Price projection assumptions

• 2023-2025: Maintenance of current prices, with slight reductions (~2-4%) driven by increasing generic competition for active ingredients.

• 2026 onwards: Expected price decline of 10-15% once multiple generics enter the market, assuming no new patents or exclusivities are secured.

• Premium positioning: If the combination demonstrates superior efficacy or safety, premium pricing may sustain, with possible increases of 5-8% over baseline.

---

Market drivers and barriers

Drivers

• Increasing prevalence of allergic rhinitis, expected to grow at a CAGR of 4% worldwide.

• Patient preference shifting toward combination therapies for convenience.

• Potential formulary inclusion driven by physician and patient demand.

Barriers

• Competition from established monotherapies.

• Patent expiry of individual components, enabling generics.

• Regulatory hurdles for approval of new formulations or delivery systems.

---

Strategic considerations

• Accelerating patent applications for new delivery systems could extend market exclusivity.

• Partnering with payers to secure formulary placement enhances revenue prospects.

• Demonstrating clinical advantages may justify premium pricing compared to standard therapies.

---

Summary and outlook

Aspect	Status	Implication
Market size	~$1.9 billion (nasal corticosteroids + antihistamines)	Niche but growing segment
Competition	High, with generics and OTC options	Price erosion pressures
Patent exclusivity	Extends to 2025-2028	Revenue window narrows post-2025
Price trends	Stable, then gradual decline	Margin compression expected post-generic entry
Strategic focus	Differentiation through efficacy, delivery innovation	Critical for premium pricing and market share

---

Key takeaways

• The drug faces a mature market with significant generic competition.

• Price projections indicate decreasing margins after patent expiry, aligning with typical generics erosion.

• Current market size suggests limited upside unless differentiated or patent protections are extended.

• Market growth hinges on allergy prevalence, treatment adherence, and formulary adoption.

• Strategic positioning through innovation and partnerships remains crucial.

---

Frequently Asked Questions

1. When do patents for NDC 60219-1076 or its components expire?
   Patent protections are expected to last until 2025-2028, depending on jurisdictions and patent strategies.

2. What is the main competitive threat?
   Generic versions of fexofenadine and mometasone nasal spray, along with OTC formulations.

3. How are prices expected to change over the next five years?
   A slight decline (~10-15%) is projected post-generic entry, with potential for premium pricing if differentiated.

4. What are key market growth factors?
   Rising allergy prevalence and patient preference for combination therapies.

5. What strategies could extend market share?
   Patents on delivery systems, clinical differentiation, and formulary negotiations.

---

Citations

[1] IQVIA, "US Market Trends and Forecasts in Allergy and Rhinology Treatments," 2022.